Skip to main content

Advertisement

SpringerLink
Log in

Management of bone metastasis in prostate cancer

  • Invited Review
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Progression of bone metastases is the primary cause of death in prostate cancer, and skeletal-related events (SREs), including pathologic fractures, spinal cord compression, radiation, or surgery to bone can impair patients’ quality of life. Over the past decade, the development of cytotoxic agents, androgen-receptor-axis-targeted therapies (ARATs), and radioligand therapies has prolonged overall survival of prostate cancer patients with bone metastases and reduced the risk of SREs. The use of bone-modifying agents has also contributed to the reduced risk of SREs. Initial use of a cytotoxic agent, docetaxel, or an ARAT agent with androgen deprivation therapy (ADT) is the current approach to metastatic castration-sensitive prostate cancer. However, there is no consensus on the optimal medication for upfront use in combination with ADT, or on specific patient selection. Recently, next-generation imaging modalities, such as whole-body magnetic resonance imaging and prostate-specific membrane antigen-positron emission tomography have been utilized to detect bone metastases at an early stage. In addition, metastasis-directed therapy, such as stereotactic body radiation therapy, has been attempted. In the future, patients with bone metastatic prostate cancer will be divided into subgroups and their treatment options will be tailored to their specific characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ottosson F, Baco E, Lauritzen PM, Rud E (2021) The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer. Eur Radiol 31:2747–2753. https://doi.org/10.1007/s00330-020-07363-x

    Article  PubMed  Google Scholar 

  2. Abuzallouf S, Dayes I, Lukka H (2004) Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171:2122–2127. https://doi.org/10.1097/01.ju.0000123981.03084.06

    Article  PubMed  Google Scholar 

  3. Lin Y, Mao Q, Chen B, Wang L, Liu B, Zheng X, Xie L (2017) When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? A retrospective study. BMC Urol 17:41. https://doi.org/10.1186/s12894-017-0229-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Batson OV (1940) The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112:138–149. https://doi.org/10.1097/00000658-194007000-00016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583. https://doi.org/10.1053/hp.2000.6698

    Article  CAS  PubMed  Google Scholar 

  6. Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889–895. https://doi.org/10.1002/pros.23645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, Villeirs G, De Vos F, De Man K, Decaestecker K, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, Duthoy W, Ost P (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int 120:815–821. https://doi.org/10.1111/bju.13938

    Article  CAS  PubMed  Google Scholar 

  8. Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthews JH, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121:98–102. https://doi.org/10.1016/j.radonc.2016.07.021

    Article  PubMed  Google Scholar 

  9. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8

    Article  CAS  PubMed  Google Scholar 

  10. Lee CT, Oesterling JE (1997) Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389–394. https://doi.org/10.1016/s0094-0143(05)70385-2

    Article  CAS  PubMed  Google Scholar 

  11. EAU guidelines 2022 Prostate Cancer In. https://uroweb.org/guidelines/prostate-cancer

  12. Shibata H, Kato S, Sekine I, Abe K, Araki N et al (2016) Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese orthopedic association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open 1:e000037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Nakanishi K, Kobayashi M, Takahashi S, Nakata S, Kyakuno M, Nakaguchi K, Nakamura H (2005) Whole body MRI for detecting metastatic bone tumor: comparison with bone scintigrams. Magn Reson Med Sci 4:11–17. https://doi.org/10.2463/mrms.4.11

    Article  PubMed  Google Scholar 

  14. Lauenstein TC, Freudenberg LS, Goehde SC, Ruehm SG, Goyen M, Bosk S, Debatin JF, Barkhausen J (2002) Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 12:2091–2099. https://doi.org/10.1007/s00330-002-1344-z

    Article  PubMed  Google Scholar 

  15. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275–282

    PubMed  Google Scholar 

  16. Van Nieuwenhove S, Van Damme J, Padhani AR, Vandecaveye V, Tombal B, Wuts J, Pasoglou V, Lecouvet FE (2022) Whole-body magnetic resonance imaging for prostate cancer assessment: current status and future directions. J Magn Reson Imaging 55:653–680. https://doi.org/10.1002/jmri.27485

    Article  PubMed  Google Scholar 

  17. Sun G, Zhang YX, Liu F, Tu N (2020) Whole-body magnetic resonance imaging is superior to skeletal scintigraphy for the detection of bone metastatic tumors: a meta-analysis. Eur Rev Med Pharmacol Sci 24:7240–7252. https://doi.org/10.26355/eurrev_202007_21879

    Article  CAS  PubMed  Google Scholar 

  18. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85

    CAS  PubMed  Google Scholar 

  19. Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528–539. https://doi.org/10.1002/jcb.10661

    Article  CAS  PubMed  Google Scholar 

  20. Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, Paganelli G (2018) PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci rep Sci Rep 8:4254. https://doi.org/10.1038/s41598-018-22594-1

    Article  CAS  PubMed  Google Scholar 

  21. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7. (Epub Mar 22 2020)

    Article  CAS  PubMed  Google Scholar 

  22. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ (2021) A Phase 2/3 Prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol 206:52–61. https://doi.org/10.1097/JU.0000000000001698. (Epub Feb 26 2021)

    Article  PubMed  PubMed Central  Google Scholar 

  23. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937. https://doi.org/10.1016/j.eururo.2016.06.021. (Epub Jun 28 2016)

    Article  PubMed  Google Scholar 

  24. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ (2018) Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol 8:28–39. https://doi.org/10.1016/j.prro.2017.07.011. (Epub Jul 20 2017)

    Article  PubMed  Google Scholar 

  25. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G (2018) 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 4:686–693. https://doi.org/10.1016/j.euf.2016.11.002. (Epub Nov 15 2016)

    Article  Google Scholar 

  26. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS et al (2019) 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20:1286–1294. https://doi.org/10.1016/S1470-2045(19)30415-2. (Epub Jul 30 2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Van de Wiele C, Sathekge M, de Spiegeleer B, De Jonghe PJ, Debruyne PR, Borms M, Beels L, Maes A (2020) PSMA expression on neovasculature of solid tumors. Histol Histopathol 35:919–927. https://doi.org/10.14670/HH-18-215

    Article  PubMed  Google Scholar 

  28. Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M (2018) 68Ga-PSMA-HBED-CC uptake in cervical, celiac and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med 59:1406–1411. https://doi.org/10.2967/jnumed.117.204677

    Article  CAS  PubMed  Google Scholar 

  29. Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A (2022) Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging 49:3910–3916. https://doi.org/10.1007/s00259-022-05745-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K (2015) Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 26:368–374. https://doi.org/10.1093/annonc/mdu519

    Article  CAS  PubMed  Google Scholar 

  31. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Kilgore ML (2011) Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis 14:177–183. https://doi.org/10.1038/pcan.2011.7

    Article  CAS  PubMed  Google Scholar 

  32. Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM (2020) Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline. J Clin Oncol 38:1736–1743. https://doi.org/10.1200/JCO.19.03148

    Article  PubMed  Google Scholar 

  33. Lutz PS, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C (2017) Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 7:4 (Epub 2016 Aug 5)

    Article  PubMed  Google Scholar 

  34. Lawton AJ, Lee KA, Cheville AL, Ferrone ML, Rades D, Balboni TA, Abrahm JL (2019) Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol 37:61–71. https://doi.org/10.1200/JCO.2018.78.1211

    Article  CAS  PubMed  Google Scholar 

  35. Frost HM (1997) On our age-related bone loss: insights from a new paradigm. J Bone Miner Res 12:1539–1546. https://doi.org/10.1359/jbmr.1997.12.10.1539

    Article  CAS  PubMed  Google Scholar 

  36. Janssen Biotech, Inc (2018) Zytiga (abiraterone acetate) [prescribing information]. http://www.zytiga.com

  37. Astellas Pharma US, Inc (2018) Xtandi (enzalutamide) [prescribing information]. http://www.xtandi.com

  38. Janssen (2018) Products. Erleada (apalutamide) [prescribing information]. http://www.erleada.com

  39. Ndibe C, Wang CG, Sonpavde G (2015) Corticosteroids in the management of prostate cancer: a critical review. Curr Treat Options Oncol 16:6. https://doi.org/10.1007/s11864-014-0320-6

    Article  PubMed  Google Scholar 

  40. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol (Oxf Engl) 39:1383–1389. https://doi.org/10.1093/rheumatology/39.12.1383

    Article  Google Scholar 

  41. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143–1150. https://doi.org/10.1200/JCO.2013.51.6500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer. Lancet 377:813–822. https://doi.org/10.1016/S0140-6736(10)62344-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Smith MR, Saad F, Coleman R, Shore N, Fizazi K et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39–46. https://doi.org/10.1016/S0140-6736(11)61226-9

    Article  CAS  PubMed  Google Scholar 

  44. Nakai Y, Kanaki T, Yamamoto A, Tanaka R, Yamamoto Y, Nagahara A, Nakayama M, Kakimoto KI, Ishibashi M, Nishimura K (2021) Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents. J Bone Miner Metab 39:295–301. https://doi.org/10.1007/s00774-020-01151-9

    Article  CAS  PubMed  Google Scholar 

  45. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48–58. https://doi.org/10.1001/jama.2016.19425

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6–19. https://doi.org/10.1007/s00774-016-0810-7

    Article  CAS  Google Scholar 

  47. Rogowski P, Roach M, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, Buchner A, Stief C, Belka C, Li M (2021) Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol 16:50. https://doi.org/10.1186/s13014-021-01776-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S (2019) Novel insights into the management of oligometastatic prostate cancer: a comprehensive review. Eur Urol Oncol 2:174–188. https://doi.org/10.1016/j.euo.2018.09.005

    Article  PubMed  Google Scholar 

  49. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter Phase II trial. J Clin Oncol 36:446–453. https://doi.org/10.1200/JCO.2017.75.4853

    Article  CAS  PubMed  Google Scholar 

  50. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial. JAMA Oncol 6:650–659. https://doi.org/10.1001/jamaoncol.2020.0147

    Article  PubMed  PubMed Central  Google Scholar 

  51. Cheetham PJ, Petrylak DP (2012) Alpha particles as radiopharmaceuticals in the treatment of bone metastases:mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Oncol (Williston Park) 26:341

    Google Scholar 

  52. Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A (2017) Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res 23:4335–4346. https://doi.org/10.1158/1078-0432.CCR-16-2955

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. https://doi.org/10.1056/NEJMoa1213755

    Article  CAS  PubMed  Google Scholar 

  54. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15:738–746. https://doi.org/10.1016/S1470-2045(14)70183-4. (Epub May 13 2014)

    Article  CAS  PubMed  Google Scholar 

  55. Smith M, Parker C, Saad F, Miller K, Tombal B et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408–419. https://doi.org/10.1016/S1470-2045(18)30860-X

    Article  CAS  PubMed  Google Scholar 

  56. Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, Nole F, Fournier B, Collette L, Gillessen S (2019) Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol 37:5007. https://doi.org/10.1200/JCO.2019.37.15_suppl.5007

    Article  Google Scholar 

  57. O’Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B (2020) Radium-223 within the evolving treatment options for metastatic castration-resistant prostate cancer: recommendations from a European expert working group. Urol Oncol 3:455–463. https://doi.org/10.1016/j.euo.2019.02.007

    Article  Google Scholar 

  58. NCCN guidelines, version 4.2022 Prostate Cancer In. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

  59. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O’Sullivan JM, Radium-223 International Early Access Program Investigators (2016) Radium-223 International Early Access Program Investigators:radium-223 and concomitant therapies in patients with metastatic castration—resistant prostate cancer: an international, Early access, open-label, single-arm phase 3b trial. Lancet Oncol 17:1306–1316. https://doi.org/10.1016/S1470-2045(16)30173-5

    Article  CAS  PubMed  Google Scholar 

  60. Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K (2021) Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. Int J Clin Oncol 26:192–198. https://doi.org/10.1007/s10147-020-01776-w

    Article  CAS  PubMed  Google Scholar 

  61. Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C (2019) Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 213:275–285. https://doi.org/10.2214/AJR.18.20845. (Epub Apr 17 2019)

    Article  PubMed  Google Scholar 

  62. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091–1103. https://doi.org/10.1056/NEJMoa2107322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM et al (2021) 177Lu. Philippine Sugar Millers Association, Lu-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797–804

    Article  CAS  PubMed  Google Scholar 

  64. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Francis RJ, Gedye C, Rutherford NK, Zhang AY, McJannett MM, Stockler MR, Williams S, Martin AJ, Davis ID (2022) TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—overall survival after median follow-up of 3 years (ANZUP 1603). Abstract. J Clin Oncol 40(16_suppl) (suppl 16; abstr 5000). https://meetings.asco.org/2022-asco-annual-meeting/14368?presentation=207021#207021 Accessed 22 Jun 2022. https://doi.org/10.1200/JCO.2022.40.16_suppl.5000

  65. Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H et al (2021) Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 22:1115–1125. https://doi.org/10.1016/S1470-2045(21)00274-6

    Article  CAS  PubMed  Google Scholar 

  66. Kuo P, Hesterman J, Rahbar K, Kendi AT, Wei XX, Fang B, Adra N, Armstrong AJ, Garje R, Michalski JM, Ghebremariam S, Brackman M, Wong C, Benson T, Vogelzang NJ (2022) [68Ga] Philippine Sugar Millers Association, GA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy (abstract). J Clin Oncol 40(16_suppl):5002

    Article  Google Scholar 

  67. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. https://doi.org/10.1056/NEJMoa040720

    Article  CAS  PubMed  Google Scholar 

  68. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. https://doi.org/10.1056/NEJMoa1014618

    Article  PubMed  PubMed Central  Google Scholar 

  69. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. https://doi.org/10.1056/NEJMoa1207506

    Article  CAS  PubMed  Google Scholar 

  70. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators TROPIC (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X

    Article  CAS  PubMed  Google Scholar 

  71. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN, LATITUDE Investigators (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360. https://doi.org/10.1056/NEJMoa1704174

    Article  CAS  PubMed  Google Scholar 

  72. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A (2019) ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974–2986. https://doi.org/10.1200/JCO.19.00799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24. https://doi.org/10.1056/NEJMoa1903307

    Article  CAS  PubMed  Google Scholar 

  74. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 399:1695–1707. https://doi.org/10.1016/S0140-6736(22)00367-1

    Article  CAS  PubMed  Google Scholar 

  75. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132–1142. https://doi.org/10.1056/NEJMoa2119115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Urology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan

    Kazuo Nishimura

Authors
  1. Kazuo Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuo Nishimura.

Ethics declarations

Conflict of interest

Dr. Nishimura has received speaker honoraria from Astellas, AstraZeneca, and Bayer; in addition to research funding from Bayer outside the submitted work.

Approval of the research protocol by an Institutional Review Board

Not applicable.

Informed consent

Not applicable.

Registry and the registration no. of the study/trial

Not applicable.

Animal study

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishimura, K. Management of bone metastasis in prostate cancer. J Bone Miner Metab 41, 317–326 (2023). https://doi.org/10.1007/s00774-023-01435-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-023-01435-w

Keywords

Search

Navigation